B7-33 2mg

B7-33 is a single-chain peptide analogue derived from the B-chain of human relaxin-2, engineered to selectively activate the relaxin family peptide receptor 1 (RXFP1). Unlike native relaxin-2, B7-33 lacks agonistic activity at other relaxin receptors, offering improved receptor selectivity that makes it a valuable tool in targeted receptor pharmacology research.

The primary mechanism of action involves B7-33 binding to RXFP1 and activating downstream signalling pathways, including ERK1/2 phosphorylation and cAMP-independent signalling cascades. This activation has been associated with suppression of TGF-β–driven fibroblast-to-myofibroblast differentiation, a key process in pathological fibrosis.

In preclinical research, B7-33 has demonstrated promising results across models of cardiac fibrosis, renal fibrosis, and pulmonary fibrosis. Its cardioprotective profile has also attracted interest in heart failure research, where RXFP1 signalling plays a role in vasodilation and myocardial remodelling.

Specifications: Molecular Formula: C₁₁₃H₁₇₀N₃₂O₃₄S, Molecular Weight: 2567.8 g/mol, Purity: >98% by HPLC, CAS Number: 1802080-75-6. Supplied as a lyophilised powder; store at –20°C, protected from light and moisture. Reconstitute in sterile water or appropriate buffer prior to use.

For research purposes only. Not for human use.